Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702377 · ClinicalTrials.gov registry record · NA
Evaluation of SYSTANE Ultra Lubricant Eye Drops
A NA study of Dry Eye, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
- 1
- Study location
NCT00702377 is a NA study of Dry Eye that has completed, run by Alcon Research. The registered enrollment target is 109 participants, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00702377, a NA study of Dry Eye, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of two artificial tears in dry eye patients.
Conditions Studied
Interventions
- OTHER SYSTANE Ultra
- OTHER Optive
Study Locations (1)
Texas
- Contact Call Center for Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00702377
The ClinicalTrials.gov registry entry for NCT00702377 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (17% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which SYSTANE Ultra is the first listed.
NCT00702377 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00702377 about?
NCT00702377 is a clinical study titled "Evaluation of SYSTANE Ultra Lubricant Eye Drops". To evaluate the safety and efficacy of two artificial tears in dry eye patients.
What is the current status of trial NCT00702377?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2008-06. Estimated completion is 2008-09.
What conditions does trial NCT00702377 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT00702377?
The interventions under investigation include: SYSTANE Ultra (OTHER), Optive (OTHER).
Who is sponsoring clinical trial NCT00702377?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00702377 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The THINK Study Incidence of Neurotrophic Keratopathy)
RECRUITING · NA
-
Low Level Light Therapy & Skin Pigmentation
RECRUITING · NA
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
Acute Comfort of Lubricant Eye Drops FID 112903
COMPLETED · NA
-
Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion
COMPLETED · NA
-
Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.